CACNA1A
ENSG00000141837
Target class
Ion channel
Chromosome
19
Approved drugs
6
Clinical candidates (approved and in development)
10
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- No
- Target name
- CACNA1A
- Gene name
- Calcium voltage-gated channel subunit alpha1 A
- Gene symbol
- CACNA1A
- Protein name
- Voltage-dependent P/Q-type calcium channel subunit alpha-1A (Brain calcium channel I) (BI) (Calcium channel, L type, alpha-1 polypeptide isoform 4) (Voltage-gated calcium channel subunit alpha Cav2.1)
- Cav2.1
- EA2
- APCA
- HPCA
- FHM
- CACNL1A4
- SCA6
- MHP1
- MHP
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 21
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 304.84
- Tissue specificity (Gini)
- 0.888
- Tissue specificity (tau)
- 0.972
- KEGG gene identifiers
- hsa:773
- Protein interaction confidence
- 0.837034
- Protein interaction partners
- 58
- R-HSA-112308
- R-HSA-422356
- End position
- 13624489
- Start position
- 13206442
- Chromosome
- 19
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 10049321
- PubMed 26716990
- Tissue specificity (tau)
- 0.971964
- Expression inequality (Gini)
- 0.887756
Expression in transcripts per million
- Brain - Cerebellum
- 304.84
- Brain - Cerebellar Hemisphere
- 275.04
- Brain - Cortex
- 25.25
- Brain - Frontal Cortex (BA9)
- 21.89
- Brain - Nucleus accumbens (basal ganglia)
- 15.19
Expression in transcripts per million
- Brain - Cerebellum304.84
- Brain - Cerebellar Hemisphere275.04
- Brain - Cortex25.25
- Brain - Frontal Cortex (BA9)21.89
- Brain - Nucleus accumbens (basal ganglia)15.19
- Brain - Caudate (basal ganglia)13.73
- Brain - Anterior cingulate cortex (BA24)13.4
- Brain - Putamen (basal ganglia)10.61
- Brain - Hypothalamus9.96
- Brain - Amygdala9.42
- Brain - Hippocampus8.12
- Brain - Spinal cord (cervical c-1)5.95
- Brain - Substantia nigra5.6
- Nerve - Tibial5.16
- Pituitary3.93
- Fallopian Tube3.78
- Testis3.77
- Artery - Tibial1.74
- Small Intestine - Terminal Ileum1.62
- Cells - Cultured fibroblasts1.37
- Thyroid1.01
- Adipose - Subcutaneous0.98
- Uterus0.96
- Adipose - Visceral (Omentum)0.95
- Cells - EBV-transformed lymphocytes0.95
And 29 more, listed on the interactive page.
- GO:0007204
- GO:0050804
- GO:0070588
- GO:1904645
- GO:1904646
- GO:0005634
- GO:0005737
- GO:0005886
- GO:0016020
- GO:0042995
- GO:0001540
- GO:0005245
- GO:0005515
- GO:0008331
- GO:0019905
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (12)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Elpetrigine Voltage-gated P/Q-type calcium channel alpha-1A subunit blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker